Literature DB >> 3260158

In vivo effects of C3a on neutrophils and its contribution to inflammatory lung processes in a guinea-pig model.

T Hoffmann1, E C Böttger, H P Baum, M Messner, U Hadding, D Bitter-Suermann.   

Abstract

C3a, when injected intravenously in guinea-pigs, caused a rapid drop of circulating neutrophils and platelets. The neutropenia was reversible and followed by a neutrophilia, which reached about 200% of baseline values. Upon challenge with octa- and hexapeptide, mimicking the C-terminal sequence of C3a, neutrophils and platelets reacted in the same manner. The hexapeptide-desArg (pentapeptide without the C-terminal arginine of hexapeptide) induced no neutropenia but a significant neutrophilia. Likewise, when injected in animals with a genetic deficiency or dysfunction of the C3a-receptor, the hexapeptide caused no drop of the neutrophils, but a neutrophilia, indicating that both neutrophil reactions are mediated by different mechanisms. With the octapeptide in vivo dose-response studies were performed. Despite maximal doses of octapeptide about 40% of the neutrophils remained in circulation, indicating that some but not all PMNs are susceptible to C3a. By pretreating the animals with an inhibitor of the serum carboxypeptidase N (SCPN-Inh) the C3a-induced neutropenia could be significantly augmented. But intravenous application of the inhibitor itself caused a 20-40% reduction of neutrophils during the first hour after injection, followed by a neutrophilia. In histological studies the timecourse of neutrophil sequestration in the lung was established, showing that the initial high neutrophil content of the lung lasted for at least 1 h and declined thereafter. Structural derangements could not be detected. These observations stress the importance of C3a besides C5a as an important mediator of inflammatory processes in species, where the C3a-receptor is present on inflammatory cells such as granulocytes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3260158      PMCID: PMC1541683     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

Review 1.  Granulocyte aggregation as a manifestation of membrane interactions with complement: possible role in leukocyte margination, microvascular occlusion, and endothelial damage.

Authors:  P R Craddock; D E Hammerschmidt; C F Moldow; O Yamada; H S Jacob
Journal:  Semin Hematol       Date:  1979-04       Impact factor: 3.851

2.  Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions.

Authors:  H N Fernandez; P M Henson; A Otani; T E Hugli
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

3.  New biological activity following intravascular activation of the complement cascade.

Authors:  C E McCall; L R De Chatelet; D Brown; P Lachmann
Journal:  Nature       Date:  1974-06-28       Impact factor: 49.962

4.  Guinea pigs deficient in C2, C4, C3 or the C3a receptor.

Authors:  D Bitter-Suermann; R Burger
Journal:  Prog Allergy       Date:  1986

5.  Demonstration of high-affinity binding sites for C3a anaphylatoxin on guinea-pig platelets.

Authors:  S Becker; U Hadding; H U Schorlemmer; D Bitter-Suermann
Journal:  Scand J Immunol       Date:  1978       Impact factor: 3.487

6.  Complement fragments, alveolar macrophages, and alveolitis.

Authors:  P M Henson; K McCarthy; G L Larsen; R O Webster; P C Giclas; R B Dreisin; T E King; J O Shaw
Journal:  Am J Pathol       Date:  1979-10       Impact factor: 4.307

7.  Effects of the cleavage peptides, C3q and C3ai, from the third component of hog complement on leukocyte accumulation and vascular permeability in vivo.

Authors:  B Damerau; H G Höllerhage; W Vogt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-03       Impact factor: 3.000

8.  C4a: the third anaphylatoxin of the human complement system.

Authors:  J P Gorski; T E Hugli; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

9.  Anaphylatoxin-induced histamine release with human leukocytes: studies of C3a leukocyte binding and histamine release.

Authors:  M M Glovsky; T E Hugli; T Ishizaka; L M Lichtenstein; B W Erickson
Journal:  J Clin Invest       Date:  1979-09       Impact factor: 14.808

10.  The anaphylatoxic peptide C3a of guinea pig complement. I. Purification, physicochemical and antigenetic properties.

Authors:  S Meuer; S Becker; U Hadding; D Bitter-Suermann
Journal:  Z Immunitatsforsch Immunobiol       Date:  1978-03
View more
  7 in total

1.  C3a receptor blockade protects podocytes from injury in diabetic nephropathy.

Authors:  Marina Morigi; Luca Perico; Daniela Corna; Monica Locatelli; Paola Cassis; Claudia Elisa Carminati; Silvia Bolognini; Carlamaria Zoja; Giuseppe Remuzzi; Ariela Benigni; Simona Buelli
Journal:  JCI Insight       Date:  2020-03-12

2.  Molecular epitope identification by limited proteolysis of an immobilized antigen-antibody complex and mass spectrometric peptide mapping.

Authors:  D Suckau; J Köhl; G Karwath; K Schneider; M Casaretto; D Bitter-Suermann; M Przybylski
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

3.  Design and biological activity of a new generation of synthetic C3a analogues by combination of peptidic and non-peptidic elements.

Authors:  R Gerardy-Schahn; D Ambrosius; M Casaretto; J Grötzinger; D Saunders; A Wollmer; D Brandenburg; D Bitter-Suermann
Journal:  Biochem J       Date:  1988-10-01       Impact factor: 3.857

4.  Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury.

Authors:  Lavinia M Proctor; Thiruma V Arumugam; Ian Shiels; Robert C Reid; David P Fairlie; Stephen M Taylor
Journal:  Br J Pharmacol       Date:  2004-05-24       Impact factor: 8.739

5.  The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization.

Authors:  Mike C L Wu; Faith H Brennan; Jason P L Lynch; Susanna Mantovani; Simon Phipps; Rick A Wetsel; Marc J Ruitenberg; Stephen M Taylor; Trent M Woodruff
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-21       Impact factor: 11.205

6.  A recombinant hybrid anaphylatoxin with dual C3a/C5a activity.

Authors:  W Bautsch; T Kretzschmar; T Stühmer; A Kola; M Emde; J Köhl; A Klos; D Bitter-Suermann
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

Review 7.  Complement Therapeutics in the Multi-Organ Donor: Do or Don't?

Authors:  Judith E van Zanden; Neeltina M Jager; Mohamed R Daha; Michiel E Erasmus; Henri G D Leuvenink; Marc A Seelen
Journal:  Front Immunol       Date:  2019-02-27       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.